Recap: Inovio Pharmaceuticals Q4 Earnings
Portfolio Pulse from Benzinga Insights
Inovio Pharmaceuticals (NASDAQ:INO) reported Q4 earnings, beating estimated EPS by 13.0% with an EPS of $-1.1 versus an estimate of $-1.27. However, revenue was down $22 thousand from the same period last year. The company's past earnings performance shows a mixed trend with misses and beats in EPS over the last four quarters.
March 06, 2024 | 9:50 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Inovio Pharmaceuticals reported a better-than-expected Q4 EPS but saw a slight decline in revenue compared to the same period last year.
The positive earnings surprise could provide short-term support to INO's stock price, but the decline in revenue might temper investor enthusiasm. Historical data shows a 4% drop in share price following a miss in EPS last quarter, indicating sensitivity to earnings reports. The mixed earnings performance over the past quarters suggests that while the beat in EPS is positive, the market's reaction could be muted due to the revenue decline and past volatility in response to earnings.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100